Biotech · Private company · San Carlos, CA, US
Ihp Therapeutics, Inc.
Track this companyFree. Adds Ihp Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards3
- A novel glycan-based selectin and complement inhibitor for at-home disease-modifying rescue of pain crisis in sickle cell diseaseFiscal year 2026 · $433.3KNIH RePORTER 5UH3NS134781-03 · fetched Nov 12, 2026
- A novel glycan-based selectin and complement inhibitor for at-home disease-modifying rescue of pain crisis in sickle cell diseaseFiscal year 2025 · $982.1KNIH RePORTER 4UH3NS134781-02 · fetched Nov 12, 2026
- Development of a novel disease-modifying glycan therapeutic for early at-home intervention of acute vaso-occlusive crisis in sickle cell diseaseFiscal year 2024 · $1.2MNIH RePORTER 5R44HL167473-03 · fetched Nov 12, 2026